Cannabinoid Anion Bioavailability via Electrostatic Repulsion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of cannabinoids are limited by adverse events and reduced bioavailability due to aggregation of molecular forms, which affects their efficacy and safety profiles.
Innovation Solution
Administering cannabinoid anions, which are more rapidly absorbed and have increased bioavailability compared to their neutral conjugate acids, through pharmaceutical compositions that avoid excipients with a pKa of less than 8 or inhibit chemical interaction, thereby enhancing treatment efficacy for various health conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If molecular forms of cannabinoids are used in pharmaceutical formulations, then the formulations can be manufactured using conventional methods, but the bioavailability is reduced due to aggregation of the molecular forms
Solution Approach 1:
The patent applies parameter changes by transforming the molecular form of cannabinoids into ionic forms (cations or anions) through chemical modification. This fundamental change in the physical-chemical state of the cannabinoid molecules prevents aggregation while maintaining manufacturability, thereby resolving the contradiction between ease of manufacture and bioavailability.
2Ease of manufacture
If conventional cannabinoid formulations are administered, then they can be produced with standard excipients, but adverse events increase due to reduced efficacy from poor absorption
Solution Approach 1:
The patent modifies the chemical parameters of cannabinoids by converting them to ionic forms, which fundamentally changes their absorption characteristics. This leads to improved efficacy and reduced adverse events while maintaining formulation simplicity through the use of standard pharmaceutical excipients.
Solution Approach 2:
The patent creates composite pharmaceutical formulations that combine ionic cannabinoid forms with conventional excipients. This composite approach allows the unique properties of ionic cannabinoids (improved absorption, reduced aggregation) to be integrated into standard pharmaceutical manufacturing processes, resolving the contradiction between formulation simplicity and reduced adverse events.
3Ease of manufacture
If molecular cannabinoids are used, then the pharmaceutical can be formulated with conventional excipients, but the absorption rate decreases due to aggregation
Solution Approach 1:
The patent applies parameter changes by converting molecular cannabinoids to ionic forms (cations or anions), which fundamentally alters their physical-chemical properties. This transformation eliminates aggregation issues and dramatically increases absorption rate while maintaining compatibility with conventional pharmaceutical formulation methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cannabinoid anions demonstrate improved efficacy and safety by increasing bioavailability and rapid absorption, effectively treating a wide range of health conditions including pain, neurodegenerative diseases, autoimmune disorders, and cancer, with reduced adverse events.
Implementation Method 1
cannabinoid anions repel each other, which increases bioavailability
Implementation Method 2
The perceived onset of pharmaceutical effects caused by cannabinoid anions relative to their neutrally-charged conjugate acids suggests that cannabinoid anions are much more rapidly absorbed upon administration than their neutrally-charged conjugate acids, which increases bioavailability
Data Source
AI summary
Various aspects of this patent document relate to methods of administering cannabinoid anions to treat various health conditions.